Hsbc Holdings PLC Has $111.27 Million Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Hsbc Holdings PLC boosted its position in IQVIA Holdings Inc. (NYSE:IQVFree Report) by 20.0% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 481,113 shares of the medical research company’s stock after purchasing an additional 80,273 shares during the period. Hsbc Holdings PLC’s holdings in IQVIA were worth $111,274,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of the company. Norges Bank acquired a new stake in IQVIA during the fourth quarter worth approximately $383,705,000. Eagle Asset Management Inc. acquired a new stake in IQVIA during the third quarter worth approximately $102,982,000. iA Global Asset Management Inc. lifted its position in IQVIA by 1,225.3% during the third quarter. iA Global Asset Management Inc. now owns 320,271 shares of the medical research company’s stock worth $63,013,000 after acquiring an additional 296,105 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its position in IQVIA by 2,765.6% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 271,316 shares of the medical research company’s stock worth $53,381,000 after acquiring an additional 261,848 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its position in IQVIA by 33.4% during the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,039,436 shares of the medical research company’s stock worth $240,505,000 after acquiring an additional 260,271 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Ari Bousbib sold 31,678 shares of the company’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the transaction, the insider now owns 796,752 shares in the company, valued at $199,610,278.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Kevin C. Knightly sold 8,607 shares of the business’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the completion of the sale, the insider now directly owns 5,251 shares of the company’s stock, valued at $1,313,642.67. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Ari Bousbib sold 31,678 shares of the business’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the sale, the insider now directly owns 796,752 shares of the company’s stock, valued at $199,610,278.56. The disclosure for this sale can be found here. Company insiders own 1.60% of the company’s stock.

IQVIA Trading Up 1.1 %

IQV stock traded up $2.51 during midday trading on Monday, hitting $229.60. The stock had a trading volume of 751,300 shares, compared to its average volume of 955,480. The firm has a market cap of $41.83 billion, a P/E ratio of 31.37, a price-to-earnings-growth ratio of 2.09 and a beta of 1.52. The company has a current ratio of 0.88, a quick ratio of 0.88 and a debt-to-equity ratio of 2.02. IQVIA Holdings Inc. has a 1-year low of $167.42 and a 1-year high of $261.73. The business has a fifty day moving average price of $237.13 and a two-hundred day moving average price of $228.93.

IQVIA (NYSE:IQVGet Free Report) last released its earnings results on Thursday, May 2nd. The medical research company reported $2.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.19 by $0.11. The business had revenue of $3.74 billion for the quarter, compared to analyst estimates of $3.69 billion. IQVIA had a net margin of 9.01% and a return on equity of 29.17%. On average, sell-side analysts predict that IQVIA Holdings Inc. will post 10.11 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Evercore ISI decreased their price objective on shares of IQVIA from $275.00 to $250.00 and set an “outperform” rating on the stock in a research note on Friday, May 3rd. BTIG Research began coverage on shares of IQVIA in a research note on Tuesday, February 13th. They set a “buy” rating and a $285.00 target price on the stock. Robert W. Baird decreased their target price on shares of IQVIA from $254.00 to $245.00 and set a “neutral” rating on the stock in a research note on Friday, May 3rd. Leerink Partnrs reaffirmed an “outperform” rating on shares of IQVIA in a research note on Monday, February 26th. Finally, StockNews.com raised shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Friday, February 16th. Three research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $257.57.

Check Out Our Latest Research Report on IQVIA

IQVIA Company Profile

(Free Report)

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Featured Stories

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQVFree Report).

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.